Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cystistat plus pirarubicin intravesical perfusion to reduce THP-related complications after TUR-BT
ChiCTR-TRC-10000788Phase 4Completed
- Sponsor
- Tongji Hospital
- Start
- Dec 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Cystistat and pirarubicin in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Tongji Hospital. Primary endpoint: VAS score for bladder pain. Started Dec 2009; status: completed.
02
Drugs
Cystistatpirarubicin
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR-TRC-10000788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10000788.